Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 9, 2026, Bluejay Diagnostics, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved Amendment No. 1 (the "Plan Amendment") to the Bluejay Diagnostics, Inc. 2021 Stock Plan (the "Stock Plan"). The Plan Amendment increases the number of shares of the Company's common stock reserved for issuance under the Stock Plan by 600,000 shares (from 61 shares to 600,061 shares). The text of the Stock Plan, as amended by the Plan Amendment, is filed herewith as Exhibit 10.1 and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 9, 2026, the Company held the Annual Meeting. As of April 28, 2026, the record date for the Annual Meeting, there were 1,034,715 shares of the Company's common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 414,092 were present in person or represented by proxy, which constituted a quorum. Stockholders are entitled to one vote for each share of common stock held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.

Proposal 1. Election of Directors - The Company's stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth and Fred Zeidman to serve as directors until the Company's 2027 annual meeting of stockholders, or until their successors are duly elected and qualified.

The voting results for the proposal were as follows:

Proposal 2. Approve and adopt an amendment to the Company's amended and restated certificate of incorporation, as amended, and effect a reverse stock split of the Company's common stock - The Company's stockholders approved and adopted an amendment to the Company's certificate of incorporation to effect a reverse stock split of all of the Company's outstanding shares of common stock by one of several fixed ratios between 1-for-2 and 1-for-20 (the "Reverse Stock Split"), with the final decision as to whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split (which may not be later than June 9, 2027), and the exact ratio of the Reverse Stock Split to be determined in the future by the Company's board of directors (the "Board"), in its sole discretion and without further action by the Company's stockholders. The Board has no present intention to implement the Reverse Stock Split during the 12-month period for which approval has been obtained. The Board sought approval of the Reverse Stock Split to give the Company flexibility in the future in the event that the Company's common stock significantly declines in value and no longer meets Nasdaq's minimum $1.00 minimum bid price requirement. On June 9, 2026, the closing price of the Company's common stock was $4.50, and the Company was in compliance with all Nasdaq listing requirements.

The voting results for the proposal were as follows:

Proposal 3. Approve and adopt an amendment to the Company's stock plan to increase the number of shares available for issuance thereunder - The Company's stockholders approved and adopted the Plan Amendment to increase the number of shares of common stock issuable under the Stock Plan by 600,000 (from 61 shares to 600,061 shares).

The voting results for the proposal were as follows:

Proposal 4. Ratification of Wolf & Company, P.C. as the Company's Independent Registered Public Accounting Firm - The Company's stockholders ratified the appointment of Wolf & Company, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

The voting results for the proposal were as follows: